Clearside Biomedical, Inc. (CLSD) News
Filter CLSD News Items
CLSD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLSD News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CLSD News From Around the Web
Below are the latest news stories about CLEARSIDE BIOMEDICAL INC that investors may wish to consider to help them evaluate CLSD as an investment opportunity.
Clearside announces publication of insights on drug development, regulationClearside Biomedical (CLSD) announced that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside’s Chief Medical Officer and Executive Vice President, Head of Research and Development, Dr. Victor Chong. The article, which was published in December 2024 by Eye and Nature.com, provides a comprehensive overview of |
Analyst Sees 500% Upside for This Pharmaceutical Penny StockClearside Biomedical: Strong Buy Ratings Back Pipeline Growth and Expanding Partnerships |
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, EyeALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside’s Chief Me |
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock NowClearside Biomedical (CLSD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting Clearside’s Pipeline Programs and Suprachoroidal Delivery Technology - - Oral Presentations Delivered on ODYSSEY Wet AMD Topline Results – ALPHARETTA, Ga., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the b |
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to BuyClearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Clearside Biomedical Third Quarter 2024 Earnings: Beats ExpectationsClearside Biomedical ( NASDAQ:CLSD ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.04m (up 21% from 3Q... |
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...Clearside Biomedical Inc (CLSD) advances its wet AMD program with positive trial outcomes, while navigating financial and regulatory challenges. |
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue EstimatesClearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 310.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Recent Commercial Licensing Agreement for China by a Global Ophthalmic Pharmaceutical Company Provides Strategic Validation of Clearside’s Suprachoroidal Platform - - Comp |